NASDAQ NMS - GLOBAL MARKET · BOLT
-3.63% · -$0.1450 · Vol 10.3K
Market closed · last close 4:00 PM ET · price as of 18:34:06 ET
Bolt Biotherapeutics Inc

Bolt Biotherapeutics Inc

Biotechnology
$3.85
Card
Relationship Map

Veridion Score

BETAMEDIUM CONF · 5/6 factorsMethodology
BOLT
Bolt Biotherapeutics Inc
Tue Aug 11 · last completed session · Markets closed · resumes Wed 9:30 ET
BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

64/ 100
Veridion Score
BUY BIAS · MEDIUM confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5/6 factors with data · Tue Aug 11 · last completed session · Markets closed · resumes Wed 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is BOLT moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading BOLT catalysts
About Bolt Biotherapeutics Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2021
Employees
23
Country
US

Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$4.04
Day high
$4.08
Day low
$3.94
Previous close
$3.99
52W high
$7.09
-45.77% from high
52W low
$3.78
2% of range
Market cap
$7.7M
EPS
$-12.7800
Beta
0.48
Shares out
1.9M
Volume
10.3K
0.69× rel vol
Avg volume
14.9K
VWAP
$3.97
Price history computed in-house
1W
-2.66%
1M
+1.72%
3M
-23.10%
1Y
-30.09%
YTD
-29.68%
SMA 50 $4.19 · below
SMA 200 $4.88 · below
52W position 2%

BOLT overview

Veridion Score
64
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around BOLT.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading BOLT Form 4 filings
Public disclosures

Congress activity in BOLT

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for BOLT in the cached public ledger.

Federal contracts

BOLT contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for BOLT in this window.
Lobbying spend

BOLT lobbying filings, year to date.

Registered lobbying filings matched to Bolt Biotherapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for BOLT in this window.
Loading news for BOLT
Analyst ratings
Sovereign unlock shows live analyst consensus for BOLT.
Options
Sovereign unlock shows live options positioning for BOLT.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.